Summary: Evaluated valsartan or amlodipine in patients with hypertension AND coronary disease, cerebrovascular disease, peripheral arterial disease or left ventricular hypertrophy (high risk patients). The primary composite endpoint of 7 factors including sudden cardiac death, fatal or nonfatal MI, recent MI on autopsy, thrombolytic therapy or coronary intervention, death during coronary intervention, new heart failure and heart failure death was not different in the two groups. Amlodipine controlled blood pressure more effectively than valsartan. 

Original Publication: N Engl J Med. 2011 Dec 1;365(22):2078-87

Eponym: The Valsartan Antihypertensive Long-term Use Evaluation Trial